Irish headquartered biotechnology firm Elan has entered into a manufacturing agreement for the supply of an active pharmaceutical ingredient with Lonza Group to advance its work on Alzheimer’s Disease.
The new agreement on the ingredient, ELND005, is “fundamental to ensuring that a high quality supply of ELND005 will be available to support the advancement of the program,” said a statement from Elan.
.A recent conference highlighted the role ELND005 could have...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team